Significant Drug Approvals | Key Pharmaceuticals 09/27/2024 FDA approves imaging drug for evaluation of myocardial ischemia and infarction 9/27/2024 Flyrcado flurpiridaz F 18 FDA approves new drug for hypoparathyroidism, a rare disorder 8/12/2024 Yorvipath palopegteriparatide FDA approves treatment for adults with Alzheimer’s disease 7/02/2024 Kisunla donanemab-azbt FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults 6/24/2024 Vyvgart Hytrulo efgartigimod alfa and hyaluronidase-qvfc FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions 5/20/2024 Yesafili and Opuviz aflibercept-jbvf and aflibercept-yszy FDA approves first drug for WHIM syndrome, a rare disorder 4/29/2024 Xolremdi mavorixafor FDA approves imaging drug to assist in detection of cancerous tissue following lumpectomy 4/17/2024 Lumisight pegulicianine FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancer 3/5/2024 Jubbonti and Wyost Denosumab-bbdz FDA approves new drug under special pathway for patients receiving hemodialysis 11/15/2023 Defencath taurolidine and heparin FDA approves first biosimilar to Actemra to treat adult and pediatric arthritis 9/29/2023 Tofidence tocilizumab-bavi FDA approves multiple generics of ADHD and BED treatment 8/28/2023 Vyvanse lisdexamfetamine dimesylate FDA approves first treatment for CD55-deficient protein-losing enteropathy (CHAPLE disease) 8/18/2023 Veopoz pozelimab-bbfg FDA approves first treatment for Fibrodysplasia Ossificans Progressiva 8/17/2023 Sohonos palovarotene
